The NYT reports on how drug companies are getting access to databases that allow them to track individual doctors' prescribing practices. This information can be helpful in better pitching their drugs to doctors. This is yet another abuse of the sort that economists predict happens when the government imposes monopolies (i.e. patents) that raise prices far above marginal cost. If economists paid attention to the $300 billion industry, they would be looking for more efficient mechanisms for financing prescription drug research.